E411 (B)-Open to men and non childbearing women

Gender: Male and Female

Smoking habit: Non / Ex-smoker only

Age: 18 - 55 years old

Up to $ 1,700

BMI : 18.00 - 32.00

Food restrictions : Fast

Clinic stay

  • 18 Jun (12:00 pm) to 20 Jun (8:00 am)
  • 23 Jun (12:00 pm) to 25 Jun (8:00 am)

Return visits

  • 21 Jun (8:00 am)
  • 22 Jun (8:00 am)
  • 23 Jun (8:00 am)
  • 26 Jun (8:00 am)
  • 27 Jun (8:00 am)
  • 28 Jun (8:00 am)

Medication type

Lonafarnib is being developed to treat chronic hepatitis D virus (HDV) infection.
Dose: 50 mg lonafarnib
Ritonavir is FDA approved to treat human immunodeficiency virus (HIV). It is being used in this study as a “booster” to increase the concentration of lonafarnib in your body. A “booster” is a drug that keeps your body from breaking down a drug before it works.
Dose: 100 mg ritonavir

Notes

Women must be of non childbearing potential.

This is preliminary information and changes could occur without notice